InSite Vision Announces Date for Annual Stockholder Meeting
Business Wire - Fri Dec 19, 3:30PM CST
InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's 2015 Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Monday, March 31, 2015, for stockholders of record on February 5, 2015. The Annual Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail notice of internet availability of the definitive proxy statement for the Annual Meeting and its annual report in February 2015.
Ocular Pain - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2jg6/ocular_pain) has announced the addition of the "Ocular Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bayer AG - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/vd...cular_pain
Blepharitis Pipeline Market Review on Drugs and Companies H2 2014
PRWeb - Thu Nov 27, 9:30PM CST
The report "Blepharitis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. The report is built using data and information sourced databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Complete Report is Available @ http://www.rnrmarketresearch.com/blepharitis-...eport.html .
Cataract Therapeutic Pipeline Market Review by Companies and Drugs H2 2014 Report at RnRMarketResearch.com
PRWeb - Fri Nov 21, 7:31AM CST
The report "Cataract - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/cataract-pip...eport.html .
EYEG: ()
InSite Vision Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:03PM CST
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended September 30, 2014. Revenues for the third quarter of 2014 were $0.4 million compared to $5.3 million for the same period in 2013. In the third quarter of 2013, revenues included an additional $3.7 minimum royalty true-up payment for net sales of AzaSite(R). Net loss for the third quarter of 2014 was $3.3 million, or $0.02 per share, compared to net income of $0.6 million, or less than $0.01 per share, in the third quarter of 2013.
InSite Vision to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended September 30, 2014 on Wednesday, November 5, 2014.
Nanosphere (NSPH) Soars: Stock Adds 26.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:51AM CDT
Nanosphere, Inc. (NSPH) was a big mover last session, as its shares rose almost 27% on the day.
EBS: 27.64 (+1.28), FCSC: 2.38 (+0.04), NSPH: 0.39 (-0.01)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 21.62 (+0.37), PSTI: 2.46 (unch), ONTY: 1.89 (+0.01)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:44AM CDT
Alexion Pharmaceuticals, Inc. (ALXN) was a big mover last session, as the company saw its shares rise 6% on the day
CBM: 21.62 (+0.37), ALXN: 181.96 (+3.09), ONTY: 1.89 (+0.01)
Weakness Seen in Vital Therapies (VTL): Stock Falls 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:42AM CDT
Vital Therapies (VTL) fell over 6% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down over 26% in the past one-month time frame.
CBM: 21.62 (+0.37), VTL: 25.06 (-0.17), PDLI: 7.61 (unch)
Immunomedics (IMMU) Jumps: Stock Adds 9.1% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 8:39AM CDT
Immunomedics Inc. (IMMU) was a big mover last session, as its shares rose over 9% on the day.
IMMU: 4.41 (+0.13), CBM: 21.62 (+0.37), GILD: 91.29 (+1.84)
Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 13% on the day.
CBM: 21.62 (+0.37), CLVS: 54.58 (+0.43), GILD: 91.29 (+1.84)
Merrimack Pharmaceuticals (MACK) Soars: Stock Adds 7.4% is Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:39AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as its shares rose over7% on the day.
MACK: 10.91 (+0.36), CBM: 21.62 (+0.37), GILD: 91.29 (+1.84)
InSite Vision Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 13, 3:05PM CDT
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended June 30, 2014. Revenues for the second quarter of 2014 were $6.3 million compared to $19.2 million for the same period in 2013. In the second quarter of 2014, revenues included a $6.0 million payment for the amendment to the Akorn License and royalties for net sales of AzaSite of $0.3 million. In the second quarter of 2013, revenues included $14.5 million for the sale of Besivance royalty rights and royalties for net sales of AzaSite of $4.7 million. Net income for the second quarter of 2014 was $37.1 million, or $0.28 per share, compared to net income of $12.1 million, or $0.09 per share, in the second quarter of 2013. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes.
InSite Vision to Report Second Quarter 2014 Financial Results on August 13, 2014
Business Wire - Tue Aug 05, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended June 30, 2014 on Wednesday, August 13, 2014.
InSite Vision awarded broad US patent for bromfenac formulations, with protection through August 2029
M2 - Thu Jul 17, 8:29AM CDT
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
InSite Vision Announces the Issuance of Broad U.S. Patent Covering Bromfenac Formulations in DuraSite(R)
Business Wire - Wed Jul 16, 7:30AM CDT
InSite Vision Incorporated (OTCBB:INSV) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite's bromfenac product candidates, including BromSite(TM) (bromfenac 0.075% ophthalmic solution formulated in DuraSite, ISV-303) for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite's pipeline covered under this patent include: ISV-101 (bromfenac 0.01%-0.04% ophthalmic solution formulated in DuraSite) for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema (CME), as well as the combination of bromfenac and dexamethasone containing products such as BromDex(TM) (ISV-504). Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.
InSite Vision to Webcast Annual Meeting of Stockholders on July 16, 2014
Business Wire - Tue Jul 15, 3:44PM CDT
InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, July 16, 2014 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a live webcast of the meeting, including a corporate presentation, available on the Investor Relations page of the company's website (www.insitevision.com). For those who miss the live broadcast, an archived replay will be available shortly thereafter.
InSite Vision to submit DexaSite's NDA to US FDA for blepharitis in adults in 2015
M2 - Wed Jul 09, 5:48AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) disclosed on Tuesday that it plans to submit a New Drug Application (NDA) for DexaSite (dexamethasone 0.1% in DuraSite) for the treatment of blepharitis in adults in 2015, following completion of remaining chemistry and manufacturing work and the meeting with the US Food and Drug Administration (FDA).
InSite Vision Plans to Submit New Drug Application to FDA for DexaSite(TM) for the Treatment of Blepharitis in Adults
Business Wire - Tue Jul 08, 7:30AM CDT
--European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 2014